Drug Profile
Golimumab - Janssen Biotech
Alternative Names: Anti-TNF-alpha monoclonal antibody - Centocor/Medarex; CNTO-148; MK-8259; SCH 900259; Shinponi; Simponi; SIMPONI ARIA; Simponi Aria; Sympony; Symposony; XinpiniLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Centocor; Medarex
- Developer Centocor; Centocor Ortho Biotech; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Merck & Co; Mitsubishi Tanabe Pharma Corporation
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Phase II Type 1 diabetes mellitus
- Phase I/II Hearing disorders
- Discontinued Asthma; Cardiovascular disorders; Sarcoidosis; Uveitis
Most Recent Events
- 13 Apr 2023 Janssen completes an expanded access programme for Type-1 diabetes mellitus (In adults, In children) in USA (Subcutaneous), before April 2023 (NCT03945903)
- 09 Mar 2023 Phase-III clinical trials in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Lithuania (SC) (EudraCT2022-001825-63 )
- 28 Dec 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In adolescents, In children, In adults) in Finland (SC, Injection)